Ron Renaud, biotech’s serial CEO, is ready for a new assignment — and maybe another deal?

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

When it comes to delivering shareholder value through M&A, Ron Renaud is a biotech investor’s best friend. Over the last 10 years, all three of the companies he has helmed were sold to Big Pharma for a combined $16 billion.

With that track record — and the financial windfall it brings — no one would have begrudged Renaud, 55, had he desired to spend more time with his Cape Cod fishing buddies. But he can’t quit biotech. Weeks after overseeing the close of Cerevel Therapeutics’s $8.7 billion acquisition by AbbVie, Renaud is back as CEO of Kailera Therapeutics, a newly formed company with a pipeline of weight loss drug candidates.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Merck Ebola vaccine Ervebo shown to offer substantial protection

Merck’s Ebola vaccine offered substantial protection to people vaccinated during the 2018-2020 outbreak in the Democratic Republic of the Congo, with an effectiveness of 84%

August 21, 2024

Biden calls for election wake-up call on abortion rights — but new upheavals are fast approaching

WASHINGTON — President Biden started his sprawling national address Thursday night with a warning to Republicans: Women have rebuked attempted abortion limits in past elections,

March 8, 2024

BioLineRx’s Aphexda receives FDA approval for stem cell mobilisation

The treatment is intended for mobilising haematopoietic stem cells to peripheral blood. Credit: Terelyuk/Shutterstock.com. BioLineRx has received US Food and Drug Administration (FDA) approval for

September 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.